# Trop2-targeted PET/CT imaging with 68Ga-MY6349 improves diagnostic accuracy and influences clinical management in breast cancer

Source: https://onco.cc/key-papers/paper-yu-ga68-my6349-breast-theranostics-2026/  
OnCo record `paper-yu-ga68-my6349-breast-theranostics-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In 73 people with breast cancer, a TROP2 PET scan found more cancer deposits than a standard FDG scan, with fewer false alarms, and changed treatment for some.

## Summary

73 patients with suspected or confirmed breast cancer had both 68Ga-MY6349 and 18F-FDG PET/CT between December 2024 and April 2025. 68Ga-MY6349 found more malignant lesions (564 against 436) and fewer false positives (2 against 40). In 30 initial-staging patients it upgraded stage in 6 (20 per cent) and changed treatment in 4; in 43 restaging patients it changed management in 5 (12 per cent). Overall tumour uptake was higher (median maximum standardised uptake value 5.9 against 4.1, p < 0.001). In three patients with triple-negative breast cancer on sacituzumab tirumotecan, early changes in uptake after two cycles matched the later clinical response; the authors call this preliminary.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: Theranostics
- Year: 2026
- DOI: 10.7150/thno.136704
- Authors: Yu L, Zhao L, Zeng R, et al.
- Findings: 564 vs 436 malignant lesions; 2 vs 40 false positives compared with FDG.; Stage upgraded in 6 of 30; management changed in 4 of 30 and 5 of 43.; Early uptake change matched response in 3 TNBC patients on sacituzumab tirumotecan.
- What it means: A TROP2 scan may help stage breast cancer and, if the early signal holds, judge whether a TROP2 drug is working. It images visible disease, not residual disease after surgery.
- Caveats: Single centre; the treatment-response finding rests on three patients.

## Sources

- Yu et al., Theranostics 2026: https://doi.org/10.7150/thno.136704
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42559486/

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Imaging](https://onco.cc/fronts/imaging/)
- technologies: [PET (positron emission tomography)](https://onco.cc/technologies/pet/), [TROP2 PET](https://onco.cc/technologies/trop2-pet/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [68Ga-MY6349](https://onco.cc/drugs/ga68-my6349/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)

---
JSON: https://onco.cc/api/v1/entities/paper-yu-ga68-my6349-breast-theranostics-2026.json